Scott L Wexelblatt1, Laura P Ward2, Kimberly Torok3, Elizabeth Tisdale3, Jareen K Meinzen-Derr4, James M Greenberg2. 1. Division of Neonatology, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH; Family Birthing Center, Mercy Anderson Hospital, Cincinnati, OH. Electronic address: scott.wexelblatt@cchmc.org. 2. Division of Neonatology, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH; Family Birthing Center, Mercy Anderson Hospital, Cincinnati, OH. 3. Family Birthing Center, Mercy Anderson Hospital, Cincinnati, OH. 4. Division of Neonatology, Perinatal Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.
Abstract
OBJECTIVE: To evaluate the efficacy of a universal maternal drug testing protocol for all mothers in a community hospital setting that experienced a 3-fold increase in neonatal abstinence syndrome (NAS) over the previous 5 years. STUDY DESIGN: We conducted a retrospective cohort study between May 2012 and November 2013 after the implementation of universal maternal urine drug testing. All subjects with positive urine tests were reviewed to identify a history or suspicion of drug use, insufficient prenatal care, placental abruption, sexually transmitted disease, or admission from a justice center, which would have prompted urine testing using our previous risk-based screening guidelines. We also reviewed the records of infants born to mothers with a positive toxicology for opioids to determine whether admission to the special care nursery was required. RESULTS: Out of the 2956 maternal specimens, 159 (5.4%) positive results were recorded. Of these, 96 were positive for opioids, representing 3.2% of all maternity admissions. Nineteen of the 96 (20%) opioid-positive urine tests were recorded in mothers without screening risk factors. Seven of these 19 infants (37%) required admission to the special care nursery for worsening signs of NAS, and 1 of these 7 required pharmacologic treatment. CONCLUSION: Universal maternal drug testing improves the identification of infants at risk for the development of NAS. Traditional screening methods underestimate in utero opioid exposure.
OBJECTIVE: To evaluate the efficacy of a universal maternal drug testing protocol for all mothers in a community hospital setting that experienced a 3-fold increase in neonatal abstinence syndrome (NAS) over the previous 5 years. STUDY DESIGN: We conducted a retrospective cohort study between May 2012 and November 2013 after the implementation of universal maternal urine drug testing. All subjects with positive urine tests were reviewed to identify a history or suspicion of drug use, insufficient prenatal care, placental abruption, sexually transmitted disease, or admission from a justice center, which would have prompted urine testing using our previous risk-based screening guidelines. We also reviewed the records of infants born to mothers with a positive toxicology for opioids to determine whether admission to the special care nursery was required. RESULTS: Out of the 2956 maternal specimens, 159 (5.4%) positive results were recorded. Of these, 96 were positive for opioids, representing 3.2% of all maternity admissions. Nineteen of the 96 (20%) opioid-positive urine tests were recorded in mothers without screening risk factors. Seven of these 19 infants (37%) required admission to the special care nursery for worsening signs of NAS, and 1 of these 7 required pharmacologic treatment. CONCLUSION: Universal maternal drug testing improves the identification of infants at risk for the development of NAS. Traditional screening methods underestimate in utero opioid exposure.
Authors: Zana Percy; Cole Brokamp; Jennifer M McAllister; Patrick Ryan; Scott L Wexelblatt; Eric S Hall Journal: J Pediatr Date: 2020-05-15 Impact factor: 4.406
Authors: Meagan E Stabler; D Leann Long; Ilana R A Chertok; Peter R Giacobbi; Courtney Pilkerton; Laura R Lander Journal: J Rural Health Date: 2016-02-16 Impact factor: 4.333
Authors: Brittany L Smith; Eric S Hall; Jennifer M McAllister; Michael P Marcotte; Kenneth D R Setchell; Vandana Megaraj; Kristine L Jimenez; T John Winhusen; Scott L Wexelblatt Journal: J Perinatol Date: 2022-02-17 Impact factor: 3.225
Authors: Jana C Leary; Kathleen E Walsh; Rebecca A Morin; Elisabeth G Schainker; JoAnna K Leyenaar Journal: J Hosp Med Date: 2019-09-18 Impact factor: 2.960
Authors: Stella Protopapas; Liza Bronner Murrison; Scott L Wexelblatt; Jason T Blackard; Eric S Hall Journal: Open Forum Infect Dis Date: 2019-10-21 Impact factor: 3.835